Literature DB >> 23053351

Lack of migraine in headaches of familial dysautonomia patients.

Boris Shihman1, Israel Steiner, Ivelin Yovchev, Channa Maayan.   

Abstract

Familial Dysautonomia (FD) is an autosomal recessive genetic disease where autonomic and sensory functions are defective affecting many body systems including the vascular. Plasma level of the neurotransmitter Calcitonin Gene Related Peptide (CGRP) is decreased in FD patients. This compound has been implicated to take part in the pathogenesis of migraine. We aimed to evaluate the symptoms of headaches in FD patients and to test the hypothesis that these patients will have a low incidence of migrainous headache. Sixty-five FD patients were evaluated by a medical headache questionnaire. Mean age was 23.73 + 10.82 years (mean 21 years) and there were 37 males (57 %).Thirty-eight patients (58.5 %) described having episodic headache conforming to criteria of tension headache, and in 17 of those 38 (44.7 %) headache were dependent on changes in blood pressure, except from one patient who had complaints that matched diagnosis of acephalic migraine. None of the patients had symptoms compatible with migraine or cluster headache. Results show that the headache is a very common complaint in FD, there is lack of migraine symptoms in this group. This might be attributed to defective sensory innervation and deficiency of CGRP. FD could be regarded as a human model for CGRP deficiency when studying the pathogenesis of migraine.

Entities:  

Mesh:

Year:  2012        PMID: 23053351     DOI: 10.1007/s00702-012-0903-y

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  28 in total

1.  Incidence of familial dysautonomia in Israel 1977-1981.

Authors:  C Maayan; E Kaplan; S Shachar; O Peleg; S Godfrey
Journal:  Clin Genet       Date:  1987-08       Impact factor: 4.438

2.  Peripheral nerve abnormalities in the Riley-Day syndrome. Findings in a sural nerve biopsy.

Authors:  A J Aguayo; C P Nair; G M Bray
Journal:  Arch Neurol       Date:  1971-02

3.  Quantitative studies of sympathetic ganglia and spinal cord intermedio-lateral gray columns in familial dysautonomia.

Authors:  J Pearson; B A Pytel
Journal:  J Neurol Sci       Date:  1978-11       Impact factor: 3.181

4.  Plasma and saliva levels of nerve growth factor and neuropeptides in chronic migraine patients.

Authors:  M-U Jang; J-W Park; H-S Kho; S-C Chung; J-W Chung
Journal:  Oral Dis       Date:  2011-03       Impact factor: 3.511

5.  Survival in familial dysautonomia: Impact of early intervention.

Authors:  Felicia B Axelrod; Judith D Goldberg; Xiang Y Ye; Channa Maayan
Journal:  J Pediatr       Date:  2002-10       Impact factor: 4.406

6.  Familial risk of migraine: a population-based study.

Authors:  W F Stewart; J Staffa; R B Lipton; R Ottman
Journal:  Ann Neurol       Date:  1997-02       Impact factor: 10.422

Review 7.  Epidemiology and comorbidity of headache.

Authors:  Rigmor Jensen; Lars J Stovner
Journal:  Lancet Neurol       Date:  2008-04       Impact factor: 44.182

8.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

Authors:  Jes Olesen; Hans-Christoph Diener; Ingo W Husstedt; Peter J Goadsby; David Hall; Ulrich Meier; Stephane Pollentier; Lynna M Lesko
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

9.  Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.

Authors:  Tony W Ho; Michel D Ferrari; David W Dodick; Vince Galet; James Kost; Xiaoyin Fan; Heather Leibensperger; Samar Froman; Christopher Assaid; Christopher Lines; Hille Koppen; Paul K Winner
Journal:  Lancet       Date:  2008-11-25       Impact factor: 79.321

Review 10.  Calcitonin gene-related peptide: an update on the biology.

Authors:  Ana Recober; Andrew F Russo
Journal:  Curr Opin Neurol       Date:  2009-06       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.